As an adjunct to diet and exercise to improve glycaemic control in patients with type-II diabetes mellitus.
Vildagliptin is a dipeptidyl peptidase-4 inhibitor. By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
The usual dose is 50 mg tablet twice daily, one tabletin the morning andone tablet in the evening. Can be given with or without food.
Hypersensitivity to the active substance or to any other excipients of the formulation.
Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.Not recommended in hepatic impairment, moderate or severe renal impairment. Not recommended in paediatric patients.
There are no adequate studies of vildagliptin in this population. Vildagliptin should not be used during pregnancy or lactation
Vildagliptin has a low potential for drug interactions. No clinically relavant interactions with oral antidiabetic drugs (glibenclamide, pioglitazone, metformin), amlodipine, digoxin, ramipril, simvastatin, valsartan or warfarin were observed after co-adminisatration with vildagliptin.There may be an increased risk of angioedema in patients concomitantly taking ACE-inhibitors.
Most common adverse reactions are hypoglycemia, tremor,headache, dizziness, constipation.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS